Implications of the TRIPS Patent Policy Srividhya Ragavan University of Oklahoma Law Center.

Slides:



Advertisements
Similar presentations
Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,
Advertisements

Fourth Global Congress on Combating Counterfeiting and Piracy WIPO Development Agenda: a New Global Initiative Dubai February 3 to 5, 2008 Pushpendra Rai.
TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac
KEI and IQsensato panel Proposal for a WTO Agreement on the Supply of Knowledge as a Public Good Presentation by Shandana Gulzar Khan Legal Affairs Officer.
Patent Systems in DCs and LDCs: The Need for Coherence between Patent Law and Public Policies Cairo, 6 May 2013 Mohamed Omar Gad Ministry of Foreign Affairs.
IP Rights Infringements and Enforcement Recommendation 45 of the WIPO Development Agenda 6-8 May 2013 Cairo Egypt 2013.
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
2 nd WIPO Inter-Regional Meeting on South- South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement Cairo.
Jean O. Lanjouw February, 2003 The Global Patent System and the Availability of Pharmaceuticals in Poor Countries.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Interface between patent and sui generis systems of protection of plant varieties The 1978 UPOV Act does not allow both systems to be applied to the same.
RECOMMENDATIONS BY INTELLECTUAL PROPERTY LAWYERS ON LEGAL REFORM MOSES NKOMO LL.B, MIP.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
Geographical Indications (GIs) in the Implementation of Public Policies: Best Practices and the Socio- Economic Dimension of GIs Presented at the Second.
1 Review of Art 39.3 TRIPS – interpretation and controversy Sanya Smith Third World Network 25 August 2006 Bangkok.
National symposium on Competition law: Evolution and Transition, 2012 Competition Policy for IP Issues Pradeep S Mehta Secretary General, CUTS International.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.
A revised framework for global medicine access Sanjay Basu Reblaw X.
Can we create a global trade framework for health care R&D that puts patients first? James Love Consumer Project on Technology Washington, DC Presented.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
AUDREY R. CHAPMAN, PH.D. UNIVERSITY OF CONNECTICUT HEALTH CENTER INTELLECTUAL PROPERTY AND HUMAN RIGHTS MEETING PANEL 1: IP AND HEALTH FEBRUARY 21, 2013.
Intellectual Property in the Context of Growth and Development of the World Economy Luciano Daffarra, Attorney at Law Daffarra, d’Addio & Partners China-Italy.
The WIPO Development Agenda: An Overview Geneva May, 2009 Esteban Burrone World Intellectual Property Organization.
IPRs serving innovation BioVision April Bibliotheca Alexandrina Ahmed Abdel Latif International Centre for Trade and Sustainable Development.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
1 Patents and Public Health Dr. Eric Noehrenberg Director International Trade and Market Policy, IFPMA WIPO Open Forum on the draft SPLT, Geneva, 3 March.
Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.
 .
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Trade-related policies and access to medicines ICTSD Consultation on trade policy coherence and access to medicines Geneva November 7 th 2006,
LESOTHO VALIDATION WORKSHOP 25 NOVEMBER 2014 CAILIN MORRISON RECAP – THE INTERNATIONAL CONTEXT: THE WTO, PATENTS, TRIPS FLEXIBILITIES & ACCESS TO MEDICINES.
WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,
Zimbabwe CSOs TRIPS and Access to medicines Aulline Mabika-Chapisa.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Presentation to Civil Society meeting Harare 21 January 2014.
TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.
International Trade. Trade allows nations to specialize in some products and then trade them for goods and services that are more expensive to produce.
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
The Intellectual Property Provisions of Recent US FTAs CARSTEN FINK Video Conference for Andean Countries on Intellectual Property Rights, May 4, 2005.
A Hybrid Game: Of the Blessed Intellectual Property & the Bastardized Biodiversity Srividhya Ragavan University of Oklahoma Law Center.
India 3.0: Debunking Myths Srividhya Ragavan University of Oklahoma Law Center.
The Imbalances within the WTO Srividhya Ragavan University Of Oklahoma Law Center.
The Inequals of Uruguay Srividhya Ragavan University of Oklahoma College of Law.
Infringers & Innovators: Debunking Myths Srividhya Ragavan University of Oklahoma Law Center.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
AIDS DRUGS, NATIONAL EMERGENCY & CIPRO Srividhya Ragavan Nat. Academy For Legal Studies & Research.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
Access v. Patents: We Still Can’t Get Along Srividhya Ragavan University of Oklahoma Law Center.
Dialogue on Competition Policy and Intellectual Property *
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
WTO and medicines: from Doha to Cancún
Intellectual Property Protection and Access to Medicines
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.
Trade-related policies and access to medicines
India 3.0: Debunking Myths
Policy Policy Consistency ….. ….. Complementarity
Obligation to contribute to R&D costs Use of pharmaceutical inventions without authorization of patent owners James Love. CPTech 16 April 2004 Twelfth.
Acceptance of the Protocol Amending the TRIPS Agreement
IP and Public Health patents on pharmaceutical products and access to medicines Giulio C. Zanetti, IDLO Beirut, May 2003.
Dr. Tenu Avafia HIV, Health and Development Group UNDP
Presentation transcript:

Implications of the TRIPS Patent Policy Srividhya Ragavan University of Oklahoma Law Center

Objectives of TRIPS Article 7 –Technological innovation To the mutual advantage of producers & users In a manner conducive to social & economic welfare To a balance of rights and obligations. Preamble of TRIPS –Recognizes public policy objectives of national systems –Emphasizes reducing tensions

Social and Economic Welfare Social effect: –Increase in cost of medication –Disease conditions from deprivation of generic drugs –Protests and unrest Economic effect: –Effect of AIDS in South Africa; Swaziland –Effect on International Trade SARS as an example Maskus’ paper and Heald’s reply

(Im)balance of Rights & Obligations Right to good health Patents & Right to life –Developed nations –Developing nations Diseases unique to developing nations are never addressed A right that cannot be accessedObligations Government’s role Acceptance for a postponement of rights –Difference between developing & developed nations

Mutual Advantage of Producers Poverty Penalty –Price Control & Compulsory Licensing Anthrax Indirect Price control –PhRMA v. Maine; & related cases

Effect of Poverty Penalty On Developing Countries –Inability to fulfill national obligations –On local economic conditions Lack of advantage to developed nations –Effect on international trade –Effect on pharmaceutical industry Doha Declaration Loss of markets from legitimization of generic drugs

Can’t We All Get Along Fear of Parallel Importation –Reaction to the fear of parallel importation Agreements in exchange of TOT –Video and computer industry –Onus on government –Better access leads to less price control –Promotion of technology – TRIPS objective